Desmopressin in haemophilia: The need for a standardised clinical response and individualised test regimen
- 21 June 2017
- journal article
- Published by Wiley in Haemophilia
- Vol. 23 (6) , 861-867
Abstract
Introduction: Due to interindividual variation in desmopressin response, non‐severe haemophilia A patients require desmopressin testing prior to therapeutic treatment. However, adequate response or frequency of blood sampling is not standardised in international guidelines. Consequently, various definitions and blood sampling protocols are currently applied. Interestingly, sustainability of desmopressin response is not incorporated into these definitions.Aim: To study desmopressin response rates in a cohort of non‐severe haemophilia A patients using currently accepted desmopressin response definitions. This, in order to formulate a standardised, uniform response which includes information on sustainability and to design a standardised blood sampling protocol.Methods: Currently used desmopressin responses in non‐severe haemophilia A patients were derived from a literature search. Actual desmopressin response rates were individualised in 105 non‐severe HA patients from the Erasmus University Medical Centre and classified according to current varying definitions.Results: Five response definitions were evaluated, three of which included only factor VIII (FVIII):C cut‐off levels and two also incorporated FVIII:C‐fold increase over baseline. FVIII:C‐fold increase showed no association with desmopressin response sustainability. FVIII:C 1 hour after infusion (<0.30, ≥0.30‐0.49, ≥0.50‐0.79 and ≥0.80 IU/mL) was, however, indicative of desmopressin response after 6 hours.Conclusion: We suggest standardised desmopressin response based on clinically relevant FVIII:C levels, e.g. 0.30 and 0.50 IU/mL. In addition, patients with <0.30 IU/mL FVIII:C after 1 hour (non‐responder) or ≥0.80 IU/mL (sustained responder) do not require subsequent blood sampling. However, patients with ≥0.30‐0.79 IU/mL FVIII:C after 1 hour should undergo blood sampling after 6 hours to additionally determine response sustainability.Keywords
This publication has 20 references indexed in Scilit:
- Side effects of desmopressin in patients with bleeding disordersHaemophilia, 2015
- Desmopressin in treatment of haematological disorders and in prevention of surgical bleedingBlood Reviews, 2014
- Clinical Efficacy and Determinants of Response to Treatment with Desmopressin in Mild Hemophilia ASeminars in Thrombosis and Hemostasis, 2013
- Desmopressin (DDAVP) in the management of patients with congenital bleeding disordersHaemophilia, 2013
- Response to desmopressin is strongly dependent on F8 gene mutation type in mild and moderate haemophilia AThrombosis and Haemostasis, 2013
- Guidelines for the management of hemophiliaHaemophilia, 2012
- DDAVP responsiveness in children with mild or moderate haemophilia A correlates with age, endogenous FVIII:C level and with haemophilic genotypeHaemophilia, 2011
- Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP)Journal of Thrombosis and Haemostasis, 2003
- Desmopressin: therapeutic limitations in children and adults with inherited coagulation disordersBritish Journal of Haematology, 2000
- Antidiuretic effect of desmopressin given in hemostatic dosages to healthy volunteersAmerican Journal of Hematology, 1998